You are here: Industry Insights > ADC

News List

Pharmaceutical Business Progress in China and Worldwide (April) PharmaSources
May 12, 2023
Progress in Pharmaceutical Business at Home and Abroad (April)
Antibody-Drug Conjugates - Lessons Learned Neeta Ratanghayra
May 20, 2022
Antibody-drug conjugates (ADCs) have made significant progress in tumor therapy and show a promising future.
Weekly Pharma News Review | PharmaSources.com (March 28 to April 1) PharmaSources.com
April 07, 2022
The failure of Phase III clinical trials targeting the popular target TIGIT monoclonal antibody has once again put tumor immunotherapy on the radar this week. The pharma news review of this week from March 28 to April 1 covers a total of 25 pieces of news
ADC vs PDC-- Status Quo of the R&D of ADC-PDC Drug in China and the World PharmaSources/zhulikou431
November 15, 2021
With the sustained investment in China's pharmaceutical industry and the growing attraction of China's pharmaceutical market to global innovative drugs, more projects of innovative drugs have added the listing in China as a necessary part.
A New Target in ADC: Nectin-4 PharmaSources/Yefenghong
September 14, 2021
Recently, the application for clinical trail of Mabwell's ADC drug (9MW2821) targeting Nectin-4 has been accepted by NMPA. It is the first time that domestic enterprise enters the IND stage with the same target drug.
Breaking News! The Second ADC Approved for Marketing in China PharmaSources/Xiaoyaowan
May 21, 2020
According to the NMPA website on May 13, the marketing application for Brentuximab Vedotin Injection filed by Takeda Pharmaceutical in China has been reviewed and approved, to become the second ADC approved for marketing in China.
Second ADC Therapeutic Drug Was Approved for Marketing in China CPhI.CN
May 14, 2020
Takeda Pharmaceutical's application of vebutuximab for injection has been approved and became the second ADC drug approved in the Chinese market.
Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC PR Newswire
March 18, 2025
Alphamab Oncology and CSPC jointly announced that anti-HER2 biparatopic ADC JSKN003 has been granted Breakthrough Therapy Designation by the CDE of the NMPA.
Study Results Abstracts From Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan At 2025 ASCO Genitourinary Cancers Symposium PR Newswire
February 13, 2025
Study Results Abstracts From Aac-TMT At 2025 ASCO Genitourinary Cancers Symposium
Alphamab Oncology Announces the Study for Ovarian Cancer PR Newswire
February 13, 2025
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page